Tags

Type your tag names separated by a space and hit enter

Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?
Neurol India. 2021 Mar-Apr; 69(Supplement):S59-S66.NI

Abstract

Background

Medications targeting the calcitonin gene-related peptide (CGRP) pathway are exciting and novel therapeutic options in the treatment of migraine.

Objective

In this article, we have reviewed the role of these CGRP monoclonal antibodies in patients with episodic migraine.

Materials and Methods

We did an extensive literature search for all phase 2 and 3 studies involving CGRP monoclonal antibodies in episodic migraine.

Results

Erenumab, fremanezumab, galcanezumab, and eptinezumab have all undergone phase 3 trials and have been found to be effective for episodic and chronic migraine. They have the advantage of being targeted therapies for migraine with very favorable adverse effect profiles comparable to placebo. Importantly, they are effective in subgroups of patients who have failed previous preventive therapies.

Conclusion

Increasing use of these medications will certainly revolutionize the treatment and outlook for patients with migraine all over the world.

Authors+Show Affiliations

Department of Neurology, Bangalore Medical College and Research Institute, Bangalore, Karnataka, India.Department of Neurology, Ghent University Hospital, Ghent, Belgium.NIHR-Wellcome Trust King's Clinical Research Facility, SLaM Biomedical Research Centre, King's College London, UK, and Department of Neurology, University of California, Los Angeles, CA, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

34003149

Citation

Nagaraj, Karthik, et al. "Role of Monoclonal Antibodies Against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?" Neurology India, vol. 69, no. Supplement, 2021, pp. S59-S66.
Nagaraj K, Vandenbussche N, Goadsby PJ. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today? Neurol India. 2021;69(Supplement):S59-S66.
Nagaraj, K., Vandenbussche, N., & Goadsby, P. J. (2021). Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today? Neurology India, 69(Supplement), S59-S66. https://doi.org/10.4103/0028-3886.315997
Nagaraj K, Vandenbussche N, Goadsby PJ. Role of Monoclonal Antibodies Against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today. Neurol India. 2021 Mar-Apr;69(Supplement):S59-S66. PubMed PMID: 34003149.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today? AU - Nagaraj,Karthik, AU - Vandenbussche,Nicolas, AU - Goadsby,Peter J, PY - 2021/5/18/entrez PY - 2021/5/19/pubmed PY - 2021/6/22/medline KW - Calcitonin gene-related peptide (CGRP) KW - episodic migraine KW - eptinezumab KW - erenumab KW - fremanezumab KW - galcanezumab KW - monoclonal antibodies SP - S59 EP - S66 JF - Neurology India JO - Neurol India VL - 69 IS - Supplement N2 - Background: Medications targeting the calcitonin gene-related peptide (CGRP) pathway are exciting and novel therapeutic options in the treatment of migraine. Objective: In this article, we have reviewed the role of these CGRP monoclonal antibodies in patients with episodic migraine. Materials and Methods: We did an extensive literature search for all phase 2 and 3 studies involving CGRP monoclonal antibodies in episodic migraine. Results: Erenumab, fremanezumab, galcanezumab, and eptinezumab have all undergone phase 3 trials and have been found to be effective for episodic and chronic migraine. They have the advantage of being targeted therapies for migraine with very favorable adverse effect profiles comparable to placebo. Importantly, they are effective in subgroups of patients who have failed previous preventive therapies. Conclusion: Increasing use of these medications will certainly revolutionize the treatment and outlook for patients with migraine all over the world. SN - 1998-4022 UR - https://www.unboundmedicine.com/medline/citation/34003149/Role_of_Monoclonal_Antibodies_against_Calcitonin_Gene_Related_Peptide__CGRP__in_Episodic_Migraine_Prevention:_Where_Do_We_Stand_Today L2 - http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2021;volume=69;issue=7;spage=59;epage=66;aulast=Nagaraj DB - PRIME DP - Unbound Medicine ER -